Vol 22, No 2 (2017)
Research paper
Published online: 2017-03-01

open access

Page views 185
Article views/downloads 233
Get Citation

Connect on Social Media

Connect on Social Media

Image guided SBRT for multiple liver metastases with ExacTrac Adaptive Gating

Carmen Rubio1, Ovidio Hernando-Requejo1, Daniel Zucca Aparicio2, María ALlona Krauel3, Mercedes López Gonzalez1, Juan María Pérez2, Emilio Sánchez Saugar1, Pedro Fernández Letón2
DOI: 10.1016/j.rpor.2016.07.006
Rep Pract Oncol Radiother 2017;22(2):150-157.

Abstract

Aim

To report the outcome and toxicity of sequential stereotactic body radiotherapy (SBRT) for multiple liver metastases in patients treated with ExacTrac Adaptive Gating.

Background

In selected patients with a limited number of liver metastases, SBRT has been evaluated as a safe and effective treatment, with minimal toxicity and high rates of local control.

Materials and methods

From April 2008 to October 2013, 21 patients with multiple (3–14) liver metastases (n[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]101) were treated sequentially with SBRT at our institution. Maximum tumor diameter was 7.5[[ce:hsp sp="0.25"/]]cm. Prior to treatment, internal markers were placed inside or near the tumor. CT or PET-CT simulation was used for the definition of gross tumor volume (GTV). Median planning target volume was 32.3[[ce:hsp sp="0.25"/]]cc (3.6–139.3[[ce:hsp sp="0.25"/]]cc). Treatment consisted of 3 fractions (12–20[[ce:hsp sp="0.25"/]]Gy/fraction) or 5 fractions (10[[ce:hsp sp="0.25"/]]Gy/fraction), prescribed to the 90–95% of the PTV volume. Daily intra-fraction image guidance was performed with ExacTrac Adaptive Gating. Regular follow-up included CT or PET-CT imaging.

Results

After a median of 23.2 months, the estimated local control rate was 94.4%, 80.6%, 65% and 65% after 1, 2, 3 and 4 years; the median overall survival was 62 months (95% CI 49.12–74.87) and the actuarial survival reached at 60 months was 57.6%. The univariate data analysis revealed that only primary histology other than colorectal adenocarcinoma was shown as an independent significant prognostic factor for local control (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.022). Number of treated metastases did not modify significantly the overall survival (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.51). No toxicity higher than G3 (1 patient with chest wall pain) and no radiation-induced liver disease were observed.

Conclusions

Sequential SBRT with ExacTrac Adaptive Gating for multiple liver metastases can be considered an effective, safe therapeutic option, with a low treatment-related toxicity. Excellent rates of local control and survival were obtained.

Article available in PDF format

View PDF Download PDF file



Reports of Practical Oncology and Radiotherapy